| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
FATE
Fate Therapeutics
|
Jul 10, 2026 | HOLD |
Strong Buy
+283.8% avg upside
31 analysts
|
$3.11
0.30% Upside
|
· |
|
NRIX
Nurix Therapeutics
|
Jul 10, 2026 | BUY |
Strong Buy
+39.3% avg upside
28 analysts
|
$34.00
55.48% Upside
|
· |
|
TSHA
Taysha Gene Therapies
|
Jul 01, 2026 | BUY |
Strong Buy
+138.9% avg upside
21 analysts
|
$12.00
102.96% Upside
|
-4.7% |
|
ABSI
AbSci
|
Jun 24, 2026 | BUY |
Strong Buy
+17.5% avg upside
18 analysts
|
$11.00
6.37% Upside
|
+5.2% |
|
CRSP
Crispr Therapeutics AG
|
Jun 24, 2026 | BUY |
Buy
+46.6% avg upside
41 analysts
|
$82.00
58.75% Upside
|
-0.4% |
|
TCRX
TScan Therapeutics
|
Jun 23, 2026 | BUY |
Strong Buy
+704.0% avg upside
12 analysts
|
$6.00
460.80% Upside
|
+16.2% |
|
LYEL
Lyell Immunopharma
|
Jun 15, 2026 | BUY |
Buy
+71.0% avg upside
10 analysts
|
$44.00
199.72% Upside
|
+12.2% |
|
RNAC
Cartesian Therapeutics
|
Jun 09, 2026 | BUY |
Strong Buy
+259.8% avg upside
19 analysts
|
$40.00
357.14% Upside
|
+0.0% |
|
ARTV
Artiva Biotherapeutics, Inc.
|
Jun 08, 2026 | BUY |
Strong Buy
+268.6% avg upside
7 analysts
|
$41.00
347.63% Upside
|
+39.4% |
|
CELC
Celcuity
|
Jun 02, 2026 | BUY |
Strong Buy
+18.2% avg upside
16 analysts
|
$157.00
49.39% Upside
|
+17.7% |
|
IMCR
Immunocore Holdings
|
Jun 01, 2026 | BUY |
Strong Buy
+98.9% avg upside
22 analysts
|
$75.00
140.50% Upside
|
+14.6% |
|
AUTL
Autolus Therapeutics
|
May 14, 2026 | BUY |
Strong Buy
+600.4% avg upside
16 analysts
|
$10.00
551.49% Upside
|
+1.3% |
|
SLDB
Solid Biosciences
|
May 14, 2026 | BUY |
Strong Buy
+61.2% avg upside
23 analysts
|
$19.00
92.03% Upside
|
+32.2% |
|
NKTX
Nkarta
|
May 13, 2026 | BUY |
Strong Buy
+554.8% avg upside
16 analysts
|
$11.00
278.07% Upside
|
+4.9% |
|
MREO
Mereo Biopharma Group Plc
|
May 12, 2026 | BUY |
Strong Buy
+1085.4% avg upside
11 analysts
|
$3.00
815.66% Upside
|
-4.0% |
|
RCKT
Rocket Pharmaceuticals
|
May 08, 2026 | HOLD |
Buy
+339.6% avg upside
29 analysts
|
— | -18.5% |
|
RXRX
Recursion Pharmaceuticals
|
May 07, 2026 | BUY |
Buy
+135.0% avg upside
12 analysts
|
$8.00
129.21% Upside
|
+22.2% |
|
SRPT
Sarepta Therapeutics
|
May 07, 2026 | SELL |
Buy
+216.9% avg upside
49 analysts
|
— | +8.9% |
|
GERN
Geron
|
May 06, 2026 | BUY |
Strong Buy
+193.8% avg upside
19 analysts
|
$4.00
180.67% Upside
|
-1.3% |
|
STTK
Shattuck Labs
|
Nov 07, 2025 | HOLD |
Strong Buy
+257.0% avg upside
14 analysts
|
— | +261.6% |
|
NBP
NovaBridge Biosciences
|
Oct 24, 2025 | HOLD |
Strong Buy
+1017.2% avg upside
14 analysts
|
— | · |
|
NXTC
NextCure
|
Dec 27, 2024 | HOLD |
Buy
+764.9% avg upside
10 analysts
|
— | +29.8% |
|
GB:0DPB
Bavarian Nordic AS
|
Feb 16, 2023 | BUY |
Strong Buy
+90.8% avg upside
5 analysts
|
$371.00
101.48% Upside
|
· |
|
TECX
Tectonic Therapeutic
|
Dec 07, 2022 | BUY |
Strong Buy
+64.1% avg upside
24 analysts
|
$6.00
82.45% Downside
|
+78.2% |
|
SYRE
Spyre Therapeutics
|
Aug 25, 2022 | HOLD |
Strong Buy
-15.5% avg upside
23 analysts
|
— | +0.0% |
|
ATHXQ
Athersys
|
Jun 03, 2022 | HOLD |
Buy
+2996428471.4% avg upside
8 analysts
|
— | -84.0% |
|
GNCAQ
Genocea Biosciences
|
Apr 06, 2022 | BUY |
Strong Buy
+573999900.0% avg upside
10 analysts
|
$6.00
599999899.92% Upside
|
· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.